
The details of the associated transactions and a potential return-on-investment result are as follows:
Aetna Inc.(AET)
The transactions were as follows:
10/24/2013 Bought 300 AET shares @ $61.61
10/24/2013 Sold 3 AET Nov2013 $60.00 Call Options @ $2.65
A possible overall performance result (including commissions) for these Aetna Inc. covered calls is as follows:
Stock Purchase Cost: $18,491.95
= ($61.61*300+$8.95 commission)
Net Profit:
(a) Options Income: +$783.80
= 300*$2.65 - $11.20 commissions
(b) Dividend Income: +$0.00
(c) Capital Appreciation (If AET assigned at $60.00) = -$491.95
= ($60.00-$61.61)*300 - $8.95 commissions
Total Net Profit (If AET assigned at $60.00): +$291.85
= (+$783.80 +$0.00 -$491.95)
Absolute Return if Assigned (at $60.00): +1.6%
= +$291.85/$18,491.95
Annualized Return If Assigned (ARIA): +24.0%
= (+$291.85/$18,491.95)*(365/24 days)
The downside 'breakeven price' at expiration is at $58.96 ($61.61 - $2.65), which is 4.3% below the current market price of $61.61.
The 'crossover price' at expiration is $62.65 ($60.00 + $2.65). This is the price above which it would have been more profitable to simply buy-and-hold Aetna until November 15th (the Nov2013 options expiration date) rather than establishing this covered calls position.